The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
M Boussageon, A Swalduz, M Pérol - … of Anticancer Therapy, 2021 - Taylor & Francis
… a double-blind, placebo-controlled phase III trial … RELAY subgroup analyses by EGFR
ex19del and ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung …
ex19del and ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung …
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung …
H Kawachi, T Yamada, A Yoshimura… - … in medical oncology, 2023 - journals.sagepub.com
… PFS than that with erlotinib plus placebo; hence, this … erlotinib for EGFR mutation-positive
NSCLC patients with asymptomatic brain metastases, these patients are eligible for this study…
NSCLC patients with asymptomatic brain metastases, these patients are eligible for this study…
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Q Liu, X Luo, L Peng, L Yi, X Wan, X Zeng, C Tan - BMJ open, 2020 - bmjopen.bmj.com
… According to the RELAY trial, over half of patients received first … : rationale and clinical
applications for non-small-cell lung … . Atlas: randomized, double-blind, placebo-controlled, phase …
applications for non-small-cell lung … . Atlas: randomized, double-blind, placebo-controlled, phase …
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
… in patients with metastatic EGFR T790M mutation–positive … TKI erlotinib had superior PFS
compared with placebo plus … TKI erlotinib in NSCLC (17), and this study is the first study of …
compared with placebo plus … TKI erlotinib in NSCLC (17), and this study is the first study of …
[HTML][HTML] Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
G Palumbo, G Esposito, G Carillio… - … Anti-tumor Therapy, 2020 - ncbi.nlm.nih.gov
… prompted a randomized, double-blind, phase III clinical study (BeTa Trial) … Relay study
compared ramucirumab plus erlotinib against erlotinib plus placebo in EGFR mutated metastatic …
compared ramucirumab plus erlotinib against erlotinib plus placebo in EGFR mutated metastatic …
Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis
K Haeussler, X Wang, KB Winfree, Y D'yachkova… - Future …, 2022 - Future Medicine
… patients with EGFR mutation-positive (EGFRm+) advanced … patients with brain metastasis,
ramucirumab + erlotinib was … was significantly more effective than placebo + erlotinib in males …
ramucirumab + erlotinib was … was significantly more effective than placebo + erlotinib in males …
[PDF][PDF] Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
PM Totaro, C Picone, N Normanno, A Morabito - 2020 - academia.edu
… The Relay study compared ramucirumab plus erlotinib … A randomized, double-blind, phase
II study of erlotinib with or … treatment for advanced EGFR mutation-positive non squamous …
II study of erlotinib with or … treatment for advanced EGFR mutation-positive non squamous …
[HTML][HTML] … of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
… (four studies) or erlotinib plus placebo (one study) for the … that erlotinib combined with
bevacizumab or ramucirumab had the … control rate in brain metastatic patients in the erlotinib and …
bevacizumab or ramucirumab had the … control rate in brain metastatic patients in the erlotinib and …
[HTML][HTML] … with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer
T Li, K Chang, X Qiu, Z Lai, Y Luo, J Chen… - … Cancer Research, 2023 - ncbi.nlm.nih.gov
… -line treatment in patients with locally advanced or metastatic … Similarly, erlotinib plus
ramucirumab, a VEGFR2 monoclonal … as follows: (I) EGFR mutation-positive, with or without …
ramucirumab, a VEGFR2 monoclonal … as follows: (I) EGFR mutation-positive, with or without …
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
T Landre, G Des Guetz, K Chouahnia… - … of Cancer Research …, 2020 - Springer
… metastatic forms with an epidermal growth-factor–receptor (… -of-care for EGFR-mutation–positive
NSCLC was platinum-… and NEJ026 with bevacizumab, RELAY with ramucirumab). …
NSCLC was platinum-… and NEJ026 with bevacizumab, RELAY with ramucirumab). …